Xponance, Inc. Akebia Therapeutics, Inc. Transaction History
Xponance, Inc.
- $12.3 Billion
- Q3 2025
A detailed history of Xponance, Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 19,546 shares of AKBA stock, worth $33,228. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,546
Previous 19,329
1.12%
Holding current value
$33,228
Previous $70,000
25.71%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AKBA
# of Institutions
188Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...